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Background: Women with gestational diabetes (GDM) are at high risk of developing diabetes later in life. After a
GDM diagnosis, women receive prenatal care to control their blood glucose levels via diet, physical activity and
medications. Continuing such lifestyle skills into early motherhood may reduce the risk of diabetes in this high risk
population. In the Gestational Diabetes’ Effects on Moms (GEM) study, we are evaluating the comparative
effectiveness of diabetes prevention strategies for weight management designed for pregnant/postpartum women
with GDM and delivered at the health system level.
Methods/Design: The GEM study is a pragmatic cluster randomized clinical trial of 44 medical facilities at Kaiser
Permanente Northern California randomly assigned to either the intervention or usual care conditions, that
includes 2,320 women with a GDM diagnosis between March 27, 2011 and March 30, 2012. A Diabetes Prevention
Program-derived print/telephone lifestyle intervention of 13 telephonic sessions tailored to pregnant/postpartum
women was developed. The effectiveness of this intervention added to usual care is to be compared to usual care
practices alone, which includes two pages of printed lifestyle recommendations sent to postpartum women via
mail. Primary outcomes include the proportion of women who reach a postpartum weight goal and total weight
change. Secondary outcomes include postpartum glycemia, blood pressure, depression, percent of calories from fat,
total caloric intake and physical activity levels. Data were collected through electronic medical records and surveys
at baseline (soon after GDM diagnosis), 6 weeks (range 2 to 11 weeks), 6 months (range 12 to 34 weeks) and
12 months postpartum (range 35 to 64 weeks).
Discussion: There is a need for evidence regarding the effectiveness of lifestyle modification for the prevention of
diabetes in women with GDM, as well as confirmation that a diabetes prevention program delivered at the health
system level is able to successfully reach this population. Given the use of a telephonic case management model,
our Diabetes Prevention Program-derived print/telephone intervention has the potential to be adopted in other
settings and to inform policies to promote the prevention of diabetes among women with GDM.
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Gestational diabetes (GDM) is defined as carbohydrate
intolerance with onset or recognition during pregnancy
[1]. GDM affects 7-14% of the pregnancies in the U.S.
and the prevalence has increased 30-100% during the
last decade [2]. A meta-analysis [3] of 20 studies repor-
ted that among women with GDM, the risk of deve-
loping diabetes postpartum was seven times higher than
that in women with normoglycemic pregnancies. The
Diabetes Prevention Program [4] (DPP) demonstrated
that among people with impaired glucose tolerance,
intensive lifestyle intervention reduced the risk of develop-
ing diabetes by 58% in parous women with or without a
history of GDM whose pregnancies were approximately
12 years before enrollment [5]. Yet postpartum quality of
care in women with GDM (e.g., glucose testing, coun-
seling on lifestyle factors and weight management) is
suboptimal [6,7]. Young women diagnosed with GDM
often receive prenatal care from a team of providers in
order to control blood glucose levels via diet, physical
activity and medications. This focus on healthy practices
may coincide with increased motivation for healthy behav-
ior change out of concern for the infant. Continuing and
adopting such lifestyle skills into early motherhood may
reduce the risk of diabetes later in life in this high risk
population.
We previously demonstrated the feasibility of a preg-
nancy and postpartum print/telephone-based lifestyle
intervention based on the DPP curriculum [8]. The next
step was to implement this intervention at the health sys-
tem level to evaluate its translation into clinical practice.
This article describes a cluster randomized intervention
trial conducted among the 44 medical facilities of Kaiser
Permanente Northern California (KPNC) that includes
2,320 pregnant women with GDM identified during a
12-month period. A cluster randomized trial design
was selected because KPNC has a centralized print/tele-
phone-based case management system for all pregnancies
complicated by GDM across the 44 medical facilities [9].
By adapting our intervention for use in 22 randomly
selected KPNC medical facilities, we can compare its
effectiveness for weight management to KPNC’s usual
care practices for women with GDM.
Research goals
The primary research goal is to compare the effectiveness
of each intervention strategy (print/telephone-based case
management alone, i.e. usual care, or a DPP-derived print/
telephone lifestyle intervention in addition to usual care) in
helping women with GDM to: a) reach pregravid weight if
normal weight [body mass index (BMI < 25.0 kg/m2)] be-
fore pregnancy; or b) achieve a 5% reduction from their
pregravid weight if overweight or obese (BMI ≥ 25.0 kg/m2)
before pregnancy.Secondary research goals include assessing differences
between the two treatment conditions in postpartum
glycemia, blood pressure, depression, percent of calories
from fat, total caloric intake and levels of physical
activity.
Tertiary research goals include assessing whether the
effectiveness of the intervention is consistent across
women’s characteristics (specifically, race/ethnicity, preg-
ravid BMI, parity, education and health literacy).
Finally, we will determine the cost-effectiveness of the
lifestyle intervention and perform an evaluation according
to the Reach, Efficacy, Adoption, Implementation, and
Maintenance (RE-AIM) framework to assess the strengths
and weaknesses of the intervention and, potentially, guide
implementation into the health system [10].
Methods/Design
Clinical setting and usual care for women with GDM
KPNC is an integrated health care delivery system with
more than 3 million members. At the start of the trial
(March 2011), KPNC was comprised of 44 medical facil-
ities and 14 delivery hospitals managing about 33,000
births per year. KPNC membership represents about 30%
of the geographic area served, and closely approximates
the demographic characteristics of the surrounding popu-
lation [11].
In this setting, 50-g, 1-h oral glucose tolerance tests
(OGTT) are performed at KPNC clinical laboratories to
screen for GDM; 96% of KPNC pregnancies are screened
[2]. If the screening test is abnormal, a diagnostic 100-g,
3-h OGTT is performed [12]. GDM is diagnosed if 2 or
more of the 4 plasma glucose values obtained during a
100-g, 3-h OGTT meet or exceed the plasma glucose
thresholds defined by Carpenter and Coustan [12,13].
In addition to the care provided by their obstetricians,
all women with GDM receive supplemental print/tele-
phone-based care from the Regional Perinatal Service
Center (RPSC). The RPSC provides nurse case manage-
ment [9]; it is staffed by 30 nurses and 2 dietitians who
offer telephone counseling on glucose monitoring and
control, diet and physical activity during pregnancy. No
counseling is offered that specifically targets appropriate
gestational weight gain.
At 6 weeks postpartum, the RPSC sends a reminder
letter for a 75-gram OGTT to test for diabetes, as well
as printed materials on healthy lifestyle encouraging
attaining a healthy BMI, participating in 30 minutes of
physical activity a day, and healthy eating. Women are
advised to have their blood glucose level tested once a
year. If the postpartum test results indicate pre-diabetes
[14], the woman is sent printed materials explaining her
increased risk of diabetes, how to prevent diabetes and
how to sign up for educational classes on pre-diabetes
offered at her medical facility. If the postpartum test
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to repeat the 75-gram OGTT and to make an appoint-
ment with her health care provider.
Eligibility and exclusion criteria
All 44 KPNC medical facilities serviced by the RPSC are
included. Pregnant women receiving medical care at the
44 medical facilities with a diagnosis of GDM [13] be-
tween March 27, 2011 and March 30, 2012, and who
are 18 years of age or older, are potentially eligible
(n = 2,480). Women are excluded if they had a neonatal
loss (n =18) or did not have any telephone contact with
the RPSC during pregnancy (n = 142), leaving 2,320
eligible women. The postpartum telephonic intervention
is introduced as a new program being offered by the RPSC
to new mothers with a GDM history; therefore, contact
with the RPSC and willingness to participate in a case
management program for GDM offered by the health
system during pregnancy is required.
Randomization
Given significant variation in the expected number of
GDM cases per medical facility in a 12-month period
(range: 3 – 247; mean = 57.5, sd = 50.3), randomization
is blocked on medical facility size (i.e., expected number
of annual cases of GDM: <25, 25–74, ≥75). We imple-
mented a restricted randomization scheme [15], whereby
we ensured an acceptable level of between–condition
balance in expected racial/ethnic distributions and in
number of women contacted for recruitment by an un-
related observational GDM study that was ongoing at
the time of GEM study randomization. This was achieved
by eliminating all allocations that did not meet specified
balance criteria (i.e., maximum between-condition relative
difference) from among all possible treatment allocations
for the 44 medical facilities. After considering a variety of
balance criteria scenarios, we chose a 20% within stratum
and 10% overall balance criteria for each racial/ethnic
group, and a 15% between condition balance on the ex-
pected number of GDM cases with recruitment attempts
by the observational study. These criteria resulted in
44,631,615 acceptable allocations and good performance
in terms of pairwise medical facility frequencies, with 95%
of all clinic pairs (total of 946 pairs) randomized to the
same condition with probabilities of 40% to 60% (designs
resulting in many instances of cluster pairs never/rarely or
always/often randomized to the same arm threaten study
validity) [15].
With treatment conditions for enumerated allocations
labeled as groups A and B, one allocation was randomly
chosen via a random number generator, with the seed
supplied by a non-study staff person (SAS® software
function RANUNI) [16]. At a separate time and location,
via a flip of a coin, another non-study staff person assignedgroup A and B to intervention/usual care groups, wit-
nessed by the GEM study biostatistician (C.P.Q.).
Blinding
All study investigators, biostatistician, data collectors
(study interviewers and medical assistants who measure
weight and blood pressure at the medical facilities),
health care providers, and RPSC staff are blinded as to
group assignment. Treatment group assignment is only
known by the programmer of the study database.
Usual care
Women receiving health care at KPNC medical facilities
randomized to the usual care condition receive the stand-
ard telephone calls from the RPSC during pregnancy, as
well as the RPSC’s postpartum printed educational mate-
rials previously described.
Lifestyle intervention
In addition to usual care, women from the medical facil-
ities assigned to the intervention condition receive a
print/telephone-based lifestyle program, similar to the
DPP curriculum, called “Getting in Balance” (GIB). The
program is delivered on behalf of the RPSC in English and
Spanish; sessions requiring other languages were de-
livered through a KPNC medical interpreter service.
Following the design of the DPP [17], the program
provides specific diet, physical activity and weight goals.
Methods to achieve those goals are individualized to
women’s preferences, resources, and cultural context using
motivational interviewing and theoretical constructs de-
rived from social cognitive theory (SCT) [18] and the
Transtheoretical Model (TTM) [19], which have been
used extensively in home-based and self-management pro-
grams [19,20]. Thus, the counseling approach addresses
stages of change [21,22], self-efficacy [20,23], and social
support for lifestyle behaviors [24].
The intervention consists of three phases: pregnancy
phase I, early postpartum phase II, and late postpartum
phase III (Table 1).
Pregnancy phase I
The target for the lifestyle program during pregnancy is
to help women adhere to Institute of Medicine (IOM)
guidelines for gestational weight gain [25]. Immediately
following diagnosis with GDM, women are mailed a
letter specifying a goal for total gestational weight gain
by the end of pregnancy. The goal is tailored to women’s
pregravid BMI and gestational weight gain trajectory
(i.e., amount of weight gained relative to weeks of
gestation). Since this population is at increased risk for
having a larger than average infant and developing
diabetes later in life, women who were normal weight
(BMI 18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2), or
Table 1 Components of the getting in balance intervention: the Gestational Diabetes’ Effects on Moms (GEM) study
Phase Component Topic Modality
Pregnancy phase I Gestational weight gain letter Goals for gestational weight gain tailored to pregravid
BMI and current weight gain trajectory
Mail
Early postpartum phase II Session 1 Intervention overview; healthy eating Telephone
Session 2 Dietary fat Telephone
Session 3 Low-fat healthy eating Telephone
Session 4 Physical activity Telephone
Session 5 Handling challenging feelings and triggers Telephone
Session 6 Healthy eating for weight loss Telephone
Session 7 Healthy eating out Telephone
Session 8 Managing setbacks Telephone
Session 9 Physical activity Telephone
Session 10 Healthy eating during social activities Telephone
Session 11 Managing stress Telephone
Session 12 Negative thoughts Telephone
Session 13 Staying motivated; relapse prevention Telephone
Late postpartum phase III Newsletter 1 Behavioral strategies (e.g., self-monitoring; problem solving) Mail
Newsletter 2 Dietary tips; stress management; social support Mail
Newsletter 3 Physical activity and dietary tips; behavioral strategies Mail
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exceed the lower limit of IOM recommendations for their
pregravid BMI (25, 15 and 11 lbs., respectively); women
who were underweight (pregravid BMI < 18.5 kg/m2) are
advised to gain at the midpoint of the IOM recommenda-
tions (34 lbs.) [25]. The letter explains that GDM increases
diabetes risk, describes how weight management can aid
in prevention, and provides healthy eating and physical ac-
tivity tips to help women achieve their gestational weight
gain goal.
Early postpartum phase II
The primary target of the intervention in the early post-
partum period is to help women lose the weight they
gained during pregnancy if they were normal weight be-
fore pregnancy (BMI <25.0 kg/m2), or lose an additional
5% of their pregravid body weight if they were over-
weight or obese before pregnancy (BMI ≥25.0 kg/m2).
At two weeks postpartum, women are mailed a work-
book of 13 sessions through which they were guided via
30-minute (Session 1) and 15-minute telephone calls (Ses-
sions 2–13). They also receive a fat gram and calorie
counter booklet, diaries to self-monitor weight, diet, and
physical activity, self-addressed stamped envelopes to
return diaries to lifestyle coaches, and brochures with
postpartum physical activity and healthy eating tips.
Women are also referred to an interactive program-
specific website. Session 1 is scheduled to occur at
approximately 6 weeks postpartum, with weekly sessions
occurring up to 6 months postpartum.Women are encouraged to set weekly goals for daily
intake of fat (in grams) and calories (for women not
achieving their weight loss goals by monitoring fat
alone). Women are encouraged to gradually work up to
150 minutes of moderate to vigorous intensity physical
activity per week, starting with short bouts and gradually
increasing frequency and duration. Women are encour-
aged to self-monitor weight, dietary intake and physical
activity using diaries. Women are also encouraged to
breastfeed and given information on when specific foods
should be introduced to their infants.
Late postpartum phase III
The target of the intervention in the late postpartum
period is to foster women’s independent maintenance of
weight loss via previously adopted lifestyle behaviors.
Women are sent 3 maintenance letters between 33 and
52 weeks postpartum, encouraging active problem-solving
of barriers after contact with the lifestyle coaches has
ended. Letters are accompanied by diaries to encourage
continued self-monitoring.
Lifestyle coaches
Bilingual (English/Spanish) coaches are located at the
RPSC. They were jointly hired by the RPSC and study
investigators, but paid with study funds. Coaches are
dietitians trained in physical activity, social cognitive
strategies, and motivational interviewing techniques to
promote health behavior change with an emphasis on
tailoring recommendations to meet the needs of diverse
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perts at KPNC and the University of Hawaii who trained
coaches as a group and as individuals using an interven-
tion protocol, case illustrations, teleconferences, and role
play. Whenever possible, women interact with the same
coach to promote continuity of care.
Intervention fidelity
Intervention fidelity is systematically assessed across
multiple dimensions [26]. The trial design offers women
a standard “dose,” or number, duration, frequency, and
format of intervention contacts. Delivery is further stan-
dardized through written protocols, scripts, and program
materials. Lifestyle coaches document process measures,
e.g., session attendance, in an electronic tracking system.
Adherence to the intervention protocol is monitored
through process measures, audiotaped sessions, and
regular group and individual supervision.
Outcomes
Primary outcomes include the proportion of women who
reach their postpartum weight goal and the amount of
total weight change. Secondary outcomes include post-
partum glycemia, blood pressure, depression score, per-
cent of calories from fat, total daily caloric intake and
physical activity levels. Study outcomes were collected at
baseline (shortly after diagnosis with GDM) and at or
near 6 weeks (range 2 to 11 weeks), 6 months (range 12
to 34 weeks) and 12 months (range 35 to 64 weeks)
postpartum via two sources: 1) the electronic medical
record (EMR) and 2) surveys (Table 2).
Weight, height, blood pressure, and blood glucose are
measured in conjunction with routine care during preg-
nancy and throughout the 12-month postpartum period.
Weight and blood pressure are measured at every health
system encounter, since BMI and blood pressure are
vital signs. Pregravid BMI is obtained from the EMR and
calculated from weight measured prior to pregnancy
(60.0%), from weight measured before 10 weeks of gesta-
tion (26.0%), from self-reported pregravid weight at the
time of the first prenatal clinic visit before 10 weeks of
gestation (10.5%), or self-reported at the baseline survey
(3.5%). To determine the glucose tolerance status during
the 12 months postpartum, the results of fasting glucose
tests, 75-g oral glucose tolerance tests and hemoglobin
A1c (glycated hemoglobin) are collected. All glucose
and A1c tests are performed at the KPNC regional
laboratory.
During pregnancy, the vast majority of KPNC patients
with GDM (97%) have a clinic visit at their medical
facility within 2 weeks of the diagnostic test for GDM, at
which measurements of weight and blood pressure are
taken. Postpartum clinical data are collected from the
EMR at or near 6 weeks (range 2 to 11 weeks), 6 months(range 12 to 34 weeks) and 12 months (range 35 to 64
weeks); if a woman had multiple measurements of the
outcome of interest in the range specified for a given
time point, the value closest to the anchor (e.g., 6 weeks,
6 months and 12 months postpartum) is selected. KPNC
patients with GDM receive a letter from the RPSC
reminding them to attend a check-up at 6 weeks post-
partum that includes measurements of weight, blood
pressure and blood glucose. At 6 months and 12
months postpartum, the RPSC also sends a letter, for
study purposes, reminding women to attend health
check-ups for weight, blood pressure and blood glu-
cose. Women also receive a telephone call reminding
them to attend the postpartum health check-up. If a
woman states that she is not able to attend the post-
partum health check-up, she is asked to report her
current weight.
To obtain data for the secondary outcomes of depressive
symptoms, percent of calories from fat, total daily caloric
intake, and physical activity, we also conduct surveys
(Table 2). The baseline survey is conducted shortly after
the diagnosis of GDM, in two phases. The first phase is
administered by computer-assisted telephone interview
(CATI) and includes brief questionnaires on dietary fat
intake and physical activity. The second phase of the base-
line survey is administered by mail and includes more
detailed questionnaires on diet and physical activity.
Follow-up surveys at approximately 6 weeks, 6 months,
and 12 months postpartum are administered via CATI,
online through a secure study website, or mail, based on
participant preference. The 6-month survey is done in two
phases, similar to the baseline survey. All survey modal-
ities are available in English and Spanish.
Dietary fat intake is assessed briefly using the Block
Fat Screener [29], and in detail using a validated semi-
quantitative food frequency questionnaire [30] modified
to accommodate the diverse dietary habits of the multi-
ethnic cohort of GEM participants. Physical activity is
assessed briefly using the Active Australia Survey [31] and
in more detail using a modified version of the Pregnancy
Physical Activity Questionnaire [32]. Depressive symp-
toms are assessed using the Patient Health Questionnaire
8 (PHQ-8) [28].
Recruitment and retention strategies
Women are reimbursed (by gift cards) for time spent
completing surveys: $40 for the first portion of the
baseline survey; $50 each for the second portion of the
baseline survey, the 6 week postpartum survey, and both
portions of the 6 month postpartum survey; and $70 for
the 12 month postpartum survey. Checks for $40 are
given for weight and blood pressure assessments at 6
and 12 months postpartum. No reimbursements are
provided for participating in the intervention.






(range 2 to 11 weeks)
6 months Postpartum
(range 12 to 34 weeks)
12 months Postpartum
(range 35 to 64 weeks)
Demographics
Age, race/ethnicity EMR/Survey X X
Education, country of origin, household
income and size, and ethnic identity [27]
Survey X X
Marital status, employment Survey X X X X
Smoking, alcohol use, sleep Survey X X X X
Pregravid weight and height EMR/Survey X
New pregnancy EMR/Survey X X
Outcomes
Weight EMR X X X X
Blood glucose EMR X X X X
Blood pressure EMR X X X X
Depression [28] Survey X X X X
Fat intake by a screener [29] Survey X X X X
Caloric intake and percent of calories
from fat by Block FFQ [30]
Survey X X X
Physical activity by Active Australia
Survey [31]
Survey X X X X
Physical Activity by Pregnancy
Physical Activity Questionnaire [32]
Survey X X
Health & Medical Care
Perceived health Survey X X X X
Pregnancy and postpartum care received Survey X
Medical history EMR/Survey X X
Reproductive history Survey X
Family history of diabetes and GDM Survey X
Medication use EMR/Survey X X X X
Gestational weight gain EMR
Infant feeding [33] Survey X X X
Medical visits EMR/Survey X
Health literacy [34] Survey X
Use of contraceptives Survey X X X
Adverse events EMR/Survey X X
Health status for cost evaluation [35] Survey X X X
Heath service utilization and cost EMR/Survey X X X
Psychosocial
Stage of change [21,22], Self-efficacy
[20,23] and Social support [24]
Survey X X
Perceived stress [36] Survey X X
Diabetes risk perception/knowledge [37] Survey X X
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the baseline survey during pregnancy and 1,643 (70.8%)
completed the survey at 6 weeks postpartum; 1,794
(77.3%) completed either the baseline survey or 6 weekspostpartum survey. There are no meaningful differences
in the recruitment rates between treatment conditions
(77.7% and 77.0%, respectively). Overall, responders and
non-responders are very similar in regards to several
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likely to be Non-Hispanic White (20% vs. 26%) (Table 3).
Data safety and monitoring plan
This trial is monitored by an independent Data and
Safety Monitoring Board (DSMB). The DSMB evaluates
the progress of the trial with biannual assessments of
participant recruitment, accrual and retention. We have
restricted our EMR-based assessment of adverse events
to those that could be related to the intervention (such
as ankle sprains, etc.), or serious events that required
hospitalization or a visit to the emergency department.
For women who are no longer members of the health
plan, adverse events are assessed via survey.
Evaluation of the intervention
To understand and inform the intervention’s implemen-
tation and potential for adoption by the health system
[10] we conducted semi-structured interviews with
KPNC clinical and operational leaders before the start of
the study and at the end. At the end of the early postpar-
tum phase, we will also conduct semi-structured inter-
views with the lifestyle coaches. Satisfaction with the
intervention is assessed using a mailed questionnaire at
approximately 8 months postpartum among women
who completed at least one telephone session.
Data on direct medical costs of the intervention, which
include all costs associated with implementing and main-
taining the intervention (excluding the cost of evaluation),
and all medical service costs, are collected through the
EMR and surveys. In addition, at each survey, we ask
participants if they were still KPNC members and if they
have had any medical visits outside KPNC. We also assess
perceived health status via survey with the EQ-5D [35].
Statistical analyses, power and sample size considerations
All analyses comparing the effectiveness of each interven-
tion strategy on our primary and secondary outcomes will
be by intent-to-treat, including all eligible study subjects
with measurements at all available time points, as appro-
priate to the outcome; analysis of treatment differences will
be by original treatment condition assignment, regardless
of adherence. The two primary outcomes for this study are
the achievement of the postpartum weight goals and
change in weight. Analyses will utilize marginal regression
models for estimation of population average intervention
effects, with linear mixed regression in analyses of weight
change and logistic regression with estimation via general-
ized estimating equations (GEE) in analyses of reaching the
weight goal. These regression models account for the
within medical facility correlation between patients and
within person correlation among repeated measurements,
for valid estimation of treatment effects and associated
standard errors. Variation in treatment group differencesover time will be examined via the introduction of appro-
priate cross-product (interaction) terms between groups
and time.
At the planning stage of this study, we expected a total
sample size of 2,432 women diagnosed with GDM in a
given year at the 44 facilities, and that approximately 76%
would have weight measured at/near 12 months postpar-
tum. Minimum detectable differences in the proportion
meeting weight goals ranged from 0.060 to 0.10, across
the range in expected proportion meeting goal in the usual
care condition (0.15 - 0.25) and across the range in ex-
pected intraclass correlation (0.01 - 0.05) [chi-square test
for two proportions, two-sided test, α = .05, power = .80].
For our actual sample size of 2,320 eligible women with
GDM at the 44 facilities and with an expected 70% with
weight measured at or near 12 months, the minimum de-
tectable difference in proportions ranges from 0.062 to
0.11. The minimum detectable difference in mean weight
at 12 months postpartum ranged from .16 to .23 standard
deviation units at the planning stage, with no change in
detectable effect sizes with the slightly lower actual sample
size and proportion with weight measured at or near 12
months. These calculations are conservative, given that
primary analyses will utilize multiple weight measures per
person via mixed effects regression analyses.
The human subjects committee of the Kaiser Foundation
Research Institute waived the requirement for individual
informed consent for the intervention component, given
the pragmatic, cluster randomized design [38,39]. For the
survey component, women give verbal consent to partici-
pate via telephone. Women attending medical facilities
randomized to the intervention can opt out of the lifestyle
program at any time and individuals can also refuse partici-
pation in the study surveys or postpartum health check-
ups at any time. All intervention and data assessment
materials for the GEM study have been approved by the
human subjects committee of the Kaiser Foundation
Research Institute; the trial is also registered at clinical-
trials.gov (NCT01344278).
Discussion
The GEM study will test the comparative effectiveness
of diabetes prevention strategies for women with GDM
in a real-world clinical setting. Women with GDM repre-
sent a population at high risk for diabetes and are identi-
fied by the health care system at a very young age, due to
a standard of prenatal care that includes screening for
GDM. Since fifty percent of women with GDM develop
diabetes within 5 years after delivery [40], diabetes preven-
tion programs should be initiated in the perinatal period.
As highlighted recently [41], there is a need for evidence
regarding the effectiveness of lifestyle modification for the
prevention of diabetes in women with GDM, as well as
confirmation that a diabetes prevention program delivered
Table 3 Characteristics of survey responders and non-responders: the Gestational Diabetes Effects on Moms (GEM)
study
All Sample Non-responders Responders P-value
N = 2,320 N = 526 (22.7%) N = 1,794 (77.3%)
Age, years 0.21
18–24 119 (5.13) 33 (6.3) 86 (4.8)
25–29 536 (23.1) 114 (21.7) 422 (23.5)
30–34 863 (37.2) 184 (35.0) 679 (37.9)
35–50 802 (34.6) 195 (37.1) 607 (33.8)
Race/ethnicity 0.003
African American 106 (4.6) 28 (5.3) 78 (4.4)
Asian 953 (41.1) 231 (43.9) 722 (40.3)
Pacific Islander 38 (1.6) 13 (2.5) 25 (1.4)
Hispanic 520 (22.4) 122 (23.2) 398 (22.2)
Non-hispanic white 580 (25.0) 105 (20.0) 475 (26.5)
Other 43 (1.9) 16 (3.0) 27 (1.5)
Multiracial/Multiethnic 75 (3.2) 11 (2.1) 64 (3.6)
Missing 5 (0.2) 0 (0.0) 5 (0.3)
Parity 0.88
0 964 (41.6) 210 (39.9) 754 (42.0)
1 769 (33.1) 158 (30.0) 611 (34.1)
2 334 (14.4) 75 (14.3) 259 (14.4)
≥3 208 (9.0) 46 (8.8) 162 (9.0)
Unknown 45 (1.9) 37 (7.0) 8 (0.5)
Pregravid BMI, kg/m2 0.11
<20.0 120 (5.2) 30 (5.7) 90 (5.0)
20.0–24.9 667 (28.8) 163 (31.0) 504 (28.1)
25.0–29.9 671 (28.9) 148 (28.1) 523 (29.2)
30.0–34.9 417 (18.0) 76 (14.5) 341 (19.0)
≥35.0 405 (17.5) 80 (15.2) 325 (18.1)
Missing 40 (1.7) 29 (5.5) 11 (0.6)
Gestational age at GDM diagnosis, weeks 0.75
5.6–13.9 286 (12.3) 61 (11.6) 225 (12.5)
14.0–27.9 1092 (47.1) 245 (46.6) 847 (47.2)
28.0–37.3 942 (40.6) 220 (41.8) 722 (40.3)
100-g, 3-h OGTT glucose levels, mg/dl Mean (SD) Mean (SD) Mean (SD)
Fasting 91.3 (12.5) 90.4 (12.0) 91.6 (12.6) 0.05
1-hour 198.7 (25.2) 200.4 (25.0) 198.2 (25.3) 0.08
2-hour 176.9 (26.6) 178.1 (27.8) 176.5 (26.2) 0.24
3-hour 129.2 (32.9) 130.0 (34.1) 128.9 (32.5) 0.53
Systolic blood pressure, mmHg 114.3 (13.0) 114.1 (13.5) 114.3 (12.9) 0.69
Diastolic blood pressure, mmHg 68.1 (9.3) 68.0 (9.6) 68.1 (9.2) 0.90
GDM = gestational diabetes mellitus.
BMI = Body mass index.
OGTT = oral glucose tolerance test.
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http://www.biomedcentral.com/1471-2393/14/21at the health system level is able to successfully reach this
population. Given the ethnic disparities in GDM, there is
a strong need to develop interventions that can reach di-
verse populations in real world settings to ensure that any
impact found is generalizable [41]. Most (73%) of our
GDM sample is ethnic minorities, including Asians,
Hispanics, and African-Americans, thereby enabling
our study to generate findings which are generalizable
to women from ethnic groups at high risk for diabetes. In
recent years, the U.S. has made significant investments in
comparative effectiveness research to provide scientific
evidence regarding the effectiveness of strategies for
preventing, diagnosing, treating and managing medical
conditions in clinical settings. To discover which strategies
work best in a clinical setting, pragmatic randomized trials
may provide a more robust approach than traditional
randomized trials because they are not conducted among
a specifically screened and/or select volunteer patient
population and occur within routine clinical practice
settings [42]. Our cluster randomized trial incorporates
several key characteristics of pragmatic trials, such as a
non-selective population of women with GDM (given that
96% of pregnant women are screened for GDM at KPNC),
the broad inclusion of patients with GDM (i.e., no exclu-
sions based on other medical conditions or language), an
intervention delivered at the health system level, and the
use of readily available clinical characteristics and out-
comes in the EMR.
Given the diverse racial/ethnic composition of women
in the GEM study and the use of a case management
telephonic health model to deliver the intervention, our
DPP-derived intervention has great potential to be
adopted and/or translated into other clinical settings. In
addition, the intervention uses motivational interviewing
techniques to promote changes in diet and physical
activity, thereby enhancing patient-centered communica-
tion in a healthcare setting. We expect the information
obtained from this trial will be used to inform future
pregnancy and postpartum health practices for women
with GDM, and develop public health policies related to
the prevention of diabetes in this population of young
women at high risk for diabetes.Competing interests
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